R P Baughman

Summary

Affiliation: University of Cincinnati
Country: USA

Publications

  1. ncbi request reprint Treatment of sarcoidosis
    Robert P Baughman
    Department of Medicine, University of Cincinnati Medical Center, Eden Avenue, Cincinnati, OH 45267 0565, USA
    Clin Chest Med 29:533-48, ix-x. 2008
  2. ncbi request reprint Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force
    R P Baughman
    University of Cincinnati Medical Center, Cincinnati, OH, USA
    Sarcoidosis Vasc Diffuse Lung Dis 28:56-64. 2011
  3. ncbi request reprint Difficult treatment issues in sarcoidosis
    R P Baughman
    Interstitial Lung Disease and Sarcoidosis Clinic, University of Cincinnati, Cincinnati, OH 45267 0564, USA
    J Intern Med 253:41-5. 2003
  4. pmc Pulmonary hypertension associated with sarcoidosis
    Robert P Baughman
    Department of Internal Medicine, Interstitial Lung Disease and Sarcoidosis Clinic, University of Cincinnati Medical Center, Holmes Eden Ave, Cincinnati, Ohio 45267, USA
    Arthritis Res Ther 9:S8. 2007
  5. doi request reprint Preface. Sarcoidosis
    Robert P Baughman
    Department of Medicine, University of Cincinnati Medical Center, Eden Avenue, Cincinnati, OH 45267 0565, USA
    Clin Chest Med 29:xiii-xiv. 2008
  6. ncbi request reprint Antibiotic resistance in the intensive care unit
    Robert P Baughman
    University of Cincinnati Medical Center, Holmes Hospital, Cincinnati, OH 45267, USA
    Curr Opin Crit Care 8:430-4. 2002
  7. ncbi request reprint Endpoints for clinical trials of sarcoidosis
    R P Baughman
    University of Cincinnati Medical Center, Cincinnati, OH, USA
    Sarcoidosis Vasc Diffuse Lung Dis 29:90-8. 2012
  8. ncbi request reprint Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue
    Elyse E Lower
    Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
    Chest 133:1189-95. 2008
  9. ncbi request reprint Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis
    M A Judson
    Department of Medicine, Medical University of South Carolina, Charleston 19425, USA
    Sarcoidosis Vasc Diffuse Lung Dis 16:75-86. 1999
  10. ncbi request reprint Management of ocular sarcoidosis
    R P Baughman
    Department of Internal Medicine, University of Cincinnati, Cincinnati OH, USA
    Sarcoidosis Vasc Diffuse Lung Dis 29:26-33. 2012

Detail Information

Publications83

  1. ncbi request reprint Treatment of sarcoidosis
    Robert P Baughman
    Department of Medicine, University of Cincinnati Medical Center, Eden Avenue, Cincinnati, OH 45267 0565, USA
    Clin Chest Med 29:533-48, ix-x. 2008
    ..The tumor necrosis factor antibody infliximab has proved useful in treating refractory sarcoidosis. These various agents led to a treatment strategy for the various aspects of sarcoidosis...
  2. ncbi request reprint Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force
    R P Baughman
    University of Cincinnati Medical Center, Cincinnati, OH, USA
    Sarcoidosis Vasc Diffuse Lung Dis 28:56-64. 2011
    ..Sarcoidosis patients who were African American or older were likely to have a higher COS, indicating more chronic disease. The COS may be useful in future studies of sarcoidosis...
  3. ncbi request reprint Difficult treatment issues in sarcoidosis
    R P Baughman
    Interstitial Lung Disease and Sarcoidosis Clinic, University of Cincinnati, Cincinnati, OH 45267 0564, USA
    J Intern Med 253:41-5. 2003
    ..For these patients, new agents such as thalidomide and the monoclonal antibodies to tumour necrosis factor have been occasionally helpful. This paper reviews several important issues in the management of sarcoidosis...
  4. pmc Pulmonary hypertension associated with sarcoidosis
    Robert P Baughman
    Department of Internal Medicine, Interstitial Lung Disease and Sarcoidosis Clinic, University of Cincinnati Medical Center, Holmes Eden Ave, Cincinnati, Ohio 45267, USA
    Arthritis Res Ther 9:S8. 2007
    ..Such therapy possibly could be combined with standard anti-inflammatory agents to improve outcome...
  5. doi request reprint Preface. Sarcoidosis
    Robert P Baughman
    Department of Medicine, University of Cincinnati Medical Center, Eden Avenue, Cincinnati, OH 45267 0565, USA
    Clin Chest Med 29:xiii-xiv. 2008
  6. ncbi request reprint Antibiotic resistance in the intensive care unit
    Robert P Baughman
    University of Cincinnati Medical Center, Holmes Hospital, Cincinnati, OH 45267, USA
    Curr Opin Crit Care 8:430-4. 2002
    ..General strategies for reducing antibiotic resistance, on the other hand, include varying the agents used in the ICU over time. Reduction of the duration of therapy may prove to be another method of reducing antibiotic resistance...
  7. ncbi request reprint Endpoints for clinical trials of sarcoidosis
    R P Baughman
    University of Cincinnati Medical Center, Cincinnati, OH, USA
    Sarcoidosis Vasc Diffuse Lung Dis 29:90-8. 2012
    ..For example, it was recommended that pulmonary studies should include changes in the forced vital capacity. Additionally, it was recommended that all trials should incorporate measurement of quality of life...
  8. ncbi request reprint Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue
    Elyse E Lower
    Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
    Chest 133:1189-95. 2008
    ..Fatigue is a common complaint in patients with sarcoidosis. We studied the effectiveness of dexmethylphenidate hydrochloride (d-MPH) in treating sarcoidosis-associated fatigue...
  9. ncbi request reprint Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis
    M A Judson
    Department of Medicine, Medical University of South Carolina, Charleston 19425, USA
    Sarcoidosis Vasc Diffuse Lung Dis 16:75-86. 1999
    ..Sarcoidosis is a multiorgan granulomatous disease of unknown cause. Lack of an objective system for assessment of sarcoidosis to evaluate disease course and effectiveness of therapy is a major problem...
  10. ncbi request reprint Management of ocular sarcoidosis
    R P Baughman
    Department of Internal Medicine, University of Cincinnati, Cincinnati OH, USA
    Sarcoidosis Vasc Diffuse Lung Dis 29:26-33. 2012
    ..A step wise approach to the use of cytotoxic and anti-tumor necrosis factor (TNF) antibodies has been developed for managing chronic sarcoidosis...
  11. ncbi request reprint Inhaled iloprost for sarcoidosis associated pulmonary hypertension
    R P Baughman
    Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
    Sarcoidosis Vasc Diffuse Lung Dis 26:110-20. 2009
    ..Patients with sarcoidosis associated pulmonary hypertension (SAPH) have responded to systemic prostacyclin therapy...
  12. ncbi request reprint Clinical characteristics of patients in a case control study of sarcoidosis
    R P Baughman
    University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0565, USA
    Am J Respir Crit Care Med 164:1885-9. 2001
    ..3, p < 0.0001), bone marrow (chi(2) = 18.8, p < 0.001), and extrathoracic lymph node involvement (chi(2) = 7.21, p < 0.01). We conclude that the initial presentation of sarcoidosis is related to sex, race, and age...
  13. ncbi request reprint Diagnostic strategies in Pneumocystis carinii pneumonia
    R P Baughman
    University of Cincinnati Medical Center, PO Box 670564, Cincinnati, OH 45267 0564, USA
    Front Biosci 3:e1-12. 1998
    ..In addition, the polymerase chain reaction (PCR) is successfully being used in the diagnosis of P. carinii. Overall, these techniques allow the clinician to tailor the diagnostic testing for the individual patient...
  14. ncbi request reprint Methotrexate for sarcoidosis
    R P Baughman
    Department of Medicine, University of Cincinnati Medical Center, Ohio 45267 0564, USA
    Sarcoidosis Vasc Diffuse Lung Dis 15:147-9. 1998
    ..Long term use of the drug is associated with some toxicity. Liver biopsies have proved a useful way of identifying which patients may remain on therapy...
  15. ncbi request reprint Presenting characteristics as predictors of duration of treatment in sarcoidosis
    R P Baughman
    University of Cincinnati Medical Center, 1001 Holmes, Eden Avenue, Cincinnati, OH 45267 0565, USA
    QJM 99:307-15. 2006
    ..Some sarcoidosis patients never need therapy, but many still require therapy more than 2 years after initial diagnosis...
  16. ncbi request reprint Infliximab for refractory sarcoidosis
    R P Baughman
    Department of Internal Medicine, University of Cincinnati Medical Center, OH, USA
    Sarcoidosis Vasc Diffuse Lung Dis 18:70-4. 2001
    ..Infliximab is a chimeric monoclonal antibody which specifically inhibits TNF-alpha. We investigated the efficacy of infliximab for the therapy of chronic, resistant sarcoidosis...
  17. ncbi request reprint Combination therapy for sarcoidosis
    R P Baughman
    Department of Medicine, University of Cincinnati Medical Center, 231 Albert Sabin Way, Room 6004, Cincinnati, OH 45267 0564, USA
    Sarcoidosis Vasc Diffuse Lung Dis 18:133-7. 2001
    ..Recently, the combination of cytotoxic and immune modifiers has been used for some cases of refractory sarcoidosis. The rationale use of combination therapy may enhance efficacy with reduced toxicity...
  18. ncbi request reprint Fungal infections as a complication of therapy for sarcoidosis
    R P Baughman
    Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
    QJM 98:451-6. 2005
    ..These agents may render the patient more susceptible to opportunistic infections. In addition, the fungal infection may be difficult to distinguish from the underlying sarcoidosis...
  19. ncbi request reprint Overexpression of transforming growth factor-alpha and epidermal growth factor-receptor in idiopathic pulmonary fibrosis
    R P Baughman
    Department of Internal Medicine, University of Cincinnati Medical Center, OH 45267 0564, USA
    Sarcoidosis Vasc Diffuse Lung Dis 16:57-61. 1999
    ..In order to validate this mouse as a model for idiopathic pulmonary fibrosis in humans, we studied the expression of TGF-alpha in lung tissue of patients with idiopathic pulmonary fibrosis compared to control lung tissue...
  20. ncbi request reprint Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems
    Robert P Baughman
    University of Cincinnati Medical Center, Cincinnati, Ohio 45267, USA
    Am J Clin Dermatol 9:155-61. 2008
    ..Facial lesions including lupus pernio are often a form of chronic cutaneous sarcoidosis...
  21. ncbi request reprint Diagnosis of ventilator-associated pneumonia
    Robert P Baughman
    Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267 0565, USA
    Microbes Infect 7:262-7. 2005
    ..The culture results are more meaningful if reported in a semi-quantitative model. There is increasing evidence that culture results predict mortality and can be used to direct duration and type of therapy...
  22. ncbi request reprint Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial
    Robert P Baughman
    Department of Internal Medicine, 1001 Holmes, Eden Ave, University of Cincinnati Medical Center, Cincinnati, OH 45267 0565, USA
    Chest 128:1062-47. 2005
    ..Study a tumor necrosis factor receptor antagonist (etanercept) in the treatment of chronic ocular sarcoidosis...
  23. ncbi request reprint Microbiologic diagnosis of ventilator-associated pneumonia
    Robert P Baughman
    University of Cincinnati Medical Center, 1001 Holmes, Eden Avenue, Cincinnati, OH 45627 0565, USA
    Clin Chest Med 26:81-6. 2005
    ..In addition, the clinician can be kept up to date about potential new pathogens as they occur in the intensive care unit. Knowledge of the local flora allows one to make a better choice of empiric therapy for VAP...
  24. ncbi request reprint The use of carbapenems in the treatment of serious infections
    Robert P Baughman
    Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267, USA
    J Intensive Care Med 24:230-41. 2009
    ..The newly approved carbapenem, doripenem, may help preserve the utility of the carbapenem class...
  25. ncbi request reprint Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement
    Robert P Baughman
    University of Cincinnati Medical Center, Cincinnati, OH 45267, USA
    Am J Respir Crit Care Med 174:795-802. 2006
    ..Evidence suggests that tumor necrosis factor (TNF)-alpha plays an important role in the pathophysiology of sarcoidosis...
  26. ncbi request reprint Six-minute walk test and health status assessment in sarcoidosis
    Robert P Baughman
    Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45627, USA
    Chest 132:207-13. 2007
    ..The 6-min walk test has proved useful in assessing impairment and prognosis in various lung diseases...
  27. ncbi request reprint Evidence-based therapy for cutaneous sarcoidosis
    Robert P Baughman
    Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45220, USA
    Clin Dermatol 25:334-40. 2007
    ..This review will examine the conventional treatments of cutaneous sarcoidosis and focus on the best available evidence to make recommendations on treatment...
  28. ncbi request reprint Sarcoidosis
    Robert P Baughman
    Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267 0565, USA
    Clin Dermatol 25:231. 2007
  29. ncbi request reprint Pulmonary hypertension in sarcoidosis
    Robert P Baughman
    Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
    Sarcoidosis Vasc Diffuse Lung Dis 23:108-16. 2006
    ..Pulmonary hypertension has been notreported in some patients with sarcoidosis...
  30. ncbi request reprint Novel therapies for sarcoidosis
    Robert P Baughman
    Division of Pulmonary and Critical Care Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267, USA
    Semin Respir Crit Care Med 28:128-33. 2007
    ..This review focuses on these novel therapies for sarcoidosis, including indications for use, efficacy, toxicity, and monitoring...
  31. ncbi request reprint Six-minute walk test in managing and monitoring sarcoidosis patients
    Robert P Baughman
    University of Cincinnati Medical Center, Cincinnati, Ohio, USA
    Curr Opin Pulm Med 13:439-44. 2007
    ..To describe the value and limitations of using the 6-min test in assessing patients with sarcoidosis...
  32. ncbi request reprint Technical aspects of bronchoalveolar lavage: recommendations for a standard procedure
    Robert P Baughman
    Division of Pulmonary and Critical Care Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0565, USA
    Semin Respir Crit Care Med 28:475-85. 2007
    ..This article summarizes these recommendations and discusses the variable effects they have on BAL results. The final recommendations provide a standard methodology that can be used by the largest number of pulmonologists...
  33. ncbi request reprint Diagnosis and management of spinal cord sarcoidosis
    Deborah A Bradley
    Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267 0565, USA
    Sarcoidosis Vasc Diffuse Lung Dis 23:58-65. 2006
    ..Sarcoidosis of the spinal cord is very rare, affecting less than 1% of patients with sarcoidosis...
  34. ncbi request reprint Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation
    Robert P Baughman
    Internal Medicine, University of Cincinnati, University of Cincinnati Medical Center, Cincinnati, OH 45267 0565, USA
    Chest 136:526-35. 2009
    ..In a double-blind, randomized trial of infliximab for chronic pulmonary sarcoidosis, changes in serial chest roentgenograms were examined by radiologists, blinded to order or treatment...
  35. ncbi request reprint Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agents
    Robert P Baughman
    Department of Medicine, Interstitial Lung Disease and Sarcoidosis Clinic, University of Cincinnati, Cincinnati, Ohio, USA
    Am J Clin Dermatol 5:385-94. 2004
    ..Over the next few years, it is hoped that there will be clinical trials to determine the role of each new therapy in the treatment of cutaneous sarcoidosis...
  36. doi request reprint Upper airway. 4: Sarcoidosis of the upper respiratory tract (SURT)
    Robert P Baughman
    University of Cincinnati Medical Center, Cincinnati, Ohio, USA
    Thorax 65:181-6. 2010
    ..While corticosteroids are often the initial drug of choice, there have been several reports of the effectiveness of cytotoxic agents and anti-tumour necrosis factor antibodies...
  37. ncbi request reprint Surfactant replacement for ventilator-associated pneumonia: a preliminary report
    Robert P Baughman
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0564, USA
    Respiration 69:57-62. 2002
    ..Surfactant abnormalities have been described in bacterial pneumonia...
  38. ncbi request reprint Thalidomide for chronic sarcoidosis
    Robert P Baughman
    Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
    Chest 122:227-32. 2002
    ..Lupus pernio is a skin manifestation of sarcoidosis that does not remit spontaneously, and was used as a marker of efficacy of thalidomide for sarcoidosis...
  39. ncbi request reprint Therapeutic options for sarcoidosis: new and old
    Robert P Baughman
    University of Cincinnati Medical Center, Interstitial Lung Disease and Sarcoidosis Clinic, Cincinnati, Ohio 45267 0565, USA
    Curr Opin Pulm Med 8:464-9. 2002
    ..A key cytokine in chronic sarcoidosis appears to be tumor necrosis factor. Drugs that inhibit its release or block its effect have been reported as effective for sarcoidosis...
  40. ncbi request reprint Can persistent tumor necrosis factor release lead to refractory sarcoidosis?
    Robert P Baughman
    Interstitial Lung Disease and Sarcoidosis Clinic, University of Cincinnati Medical Center, OH 45267 0565, USA
    Sarcoidosis Vasc Diffuse Lung Dis 19:164-6. 2002
  41. ncbi request reprint Use of fluticasone in acute symptomatic pulmonary sarcoidosis
    Robert P Baughman
    Department of Internal Medicine, University of Cincinnati Medical Center, OH 45267 0565, USA
    Sarcoidosis Vasc Diffuse Lung Dis 19:198-204. 2002
    ..Inhaled corticosteroids have been used with variable success in sarcoidosis. The role of the inhaled corticosteroid fluticasone in symptomatic pulmonary patients was studied...
  42. pmc A concise review of pulmonary sarcoidosis
    Robert P Baughman
    Department of Internal Medicine, University of Cincinnati Medical Center, Ohio, USA
    Am J Respir Crit Care Med 183:573-81. 2011
    ..There have been several recent studies demonstrating treatment options for these problems...
  43. ncbi request reprint Sarcoidosis
    Robert P Baughman
    Department of Internal Medicine, University of Cincinnati, Cincinnati Medical Center, Cincinnati, OH 45267 0565, USA
    Lancet 361:1111-8. 2003
    ..New agents, including pentoxifylline, thalidomide, and infliximab have proved useful in selected cases. The effectiveness of these agents seems to lie in their ability to block TNF, especially in the treatment of chronic disease...
  44. ncbi request reprint Ocular sarcoidosis
    Robert P Baughman
    Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267 0565, USA
    Semin Respir Crit Care Med 31:452-62. 2010
    ..Recent reports have demonstrated that monoclonal antibodies blocking tumor necrosis factor can be quite effective for chronic refractory ocular sarcoidosis...
  45. ncbi request reprint Nonbronchoscopic evaluation of ventilator-associated pneumonia
    Robert P Baughman
    Interstitial Lung Disease and Sarcoidosis Center, Department of Internal Medicine, University of Cincinnati Medical Center, 1001 Holmes Hospital, Eden Avenue and Albert Sabin Way, Cincinnati, OH 45267 0565, USA
    Semin Respir Infect 18:95-102. 2003
    ..By using this approach, the physician should be able to better direct therapy and reduce mortality from pneumonia in the intensive care unit (ICU)...
  46. ncbi request reprint Pulmonary sarcoidosis
    Robert P Baughman
    University of Cincinnati Medical Center, 1001 Holmes, Eden Avenue, Cincinnati, OH 45267 0565, USA
    Clin Chest Med 25:521-30, vi. 2004
    ..Treatment options include corticosteroids.In the past few years, alternatives to corticosteroids have been developed,especially for patients with a chronic condition...
  47. ncbi request reprint Leflunomide for chronic sarcoidosis
    Robert P Baughman
    Interstitial Lung Disease and Sarcoidosis Clinic, University of Cincinnati Medical Center, Cincinnati, Ohio, USA
    Sarcoidosis Vasc Diffuse Lung Dis 21:43-8. 2004
    ..It appears to have less toxicity than methotrexate. The use of leflunomide for sarcoidosis patients has not been systematically evaluated...
  48. doi request reprint Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation
    Robert P Baughman
    Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
    Chest 138:1078-85. 2010
    ..Our objective was to determine if the cause of PH affects survival in patients with sarcoidosis with persistent dyspnea...
  49. ncbi request reprint Ventilator-associated pneumonia patients who do not reduce bacteria from the lungs have a worse prognosis
    Robert P Baughman
    University of Cincinnati Medical Center, Cincinnati, OH 45267 0565, USA
    J Intensive Care Med 18:269-74. 2003
    ..The inability to reduce the bacterial burden from the lower respiratory tract within the first few days of therapy for ventilator-associated pneumonia was associated with increased mortality...
  50. ncbi request reprint Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis
    Robert P Baughman
    Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA
    Arch Intern Med 163:615-20. 2003
    ..Because sarcoidosis has a high frequency of liver involvement, we routinely perform a liver biopsy after each cumulative gram of methotrexate therapy in patients with sarcoidosis in whom we plan to continue therapy...
  51. ncbi request reprint Tumour necrosis factor in sarcoidosis and its potential for targeted therapy
    Robert P Baughman
    Interstitial Lung Disease and Sarcoidosis Clinic, University of Cincinnati Medical Center, Cincinnati, Ohio, USA
    BioDrugs 17:425-31. 2003
    ..However, as infliximab can be associated with reactivation of tuberculosis, which could be mistaken as worsening sarcoidosis, it should be used with caution in this patient group...
  52. ncbi request reprint Diagnosis of ventilator-associated pneumonia
    Robert P Baughman
    Department of Internal Medicine, University of Cincinnati Medical Center, Ohio, USA
    Curr Opin Crit Care 9:397-402. 2003
    ..This review examines the various techniques used to diagnose ventilator-associated pneumonia. The ideal diagnostic test not only helps the clinician to recognize whether pneumonia is present, but also to influence clinical outcome...
  53. ncbi request reprint Nonsteroidal therapy for idiopathic pulmonary fibrosis
    R P Baughman
    Interstitial Lung Disease and Sarcoidosis Clinic, University of Cincinnati Medical Center, Eden Avenue and Albert Sabin Way, Cincinnati, OH 45267 0565, USA
    Curr Opin Pulm Med 7:309-13. 2001
    ..The future therapy of interstitial lung disease probably will consist of multiple agents aimed at several aspects of the inflammatory reaction of interstitial lung disease...
  54. ncbi request reprint Surfactant protein deficiency in familial interstitial lung disease
    R S Amin
    Children s Hospital Medical Center, Department of Pediatrics, Cincinnati, Ohio 45229 3039, USA
    J Pediatr 139:85-92. 2001
    ..To determine the contribution of surfactant protein abnormalities to the development of chronic lung injury in a familial form of interstitial lung disease...
  55. pmc Sterols of Pneumocystis carinii hominis organisms isolated from human lungs
    E S Kaneshiro
    Department of Biological Sciences, University of Cincinnati, Cincinnati, Ohio 45221, USA
    Clin Diagn Lab Immunol 6:970-6. 1999
    ..g., fungisterol and methylcholest-7-ene-3beta-ol) previously identified in P. carinii carinii were also present in organisms isolated from human specimens. Pneumocysterol was detected in only some of the samples...
  56. ncbi request reprint The lung in the immunocompromised patient. Infectious complications Part 1
    R P Baughman
    Division of Pulmonary and Critical Care Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0564, USA
    Respiration 66:95-109. 1999
    ..In this review, we will discuss these various possible infections, their frequency of occurrence, and their clinical presentation in the various immunosuppressed groups...
  57. ncbi request reprint Treatment of sarcoidosis
    R P Baughman
    Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
    Panminerva Med 55:175-89. 2013
    ..Non immunosuppressive agents also play a role in the therapy of pulmonary sarcoidosis patients. These include treatments for pulmonary hypertension, infection, and fatigue...
  58. ncbi request reprint Infliximab in chronic ocular inflammation
    R P Baughman
    Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267 0565, USA
    Int J Clin Pharmacol Ther 43:7-11. 2005
    ..Infliximab is a chimeric antibody which binds tumor necrosis factor (TNF). It is effective in several chronic inflammatory conditions, including sarcoidosis...
  59. ncbi request reprint Managing serious infections in the hospital: a new model
    R P Baughman
    Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
    Clin Microbiol Infect 11:1-3. 2005
  60. ncbi request reprint Breast disease in sarcoidosis
    E E Lower
    University of Cincinnati Medical Center, Department of Medicine, Ohio 45267-0562, USA
    Sarcoidosis Vasc Diffuse Lung Dis 18:301-6. 2001
    ..Because physical examination and mammography findings are unable to distinguish between sarcoidosis and malignancy, biopsy of all suspicious lesions in sarcoidosis is recommended...
  61. ncbi request reprint Role of bronchoalveolar lavage in interstitial lung disease
    R P Baughman
    Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio, USA
    Clin Chest Med 22:331-41. 2001
    ..Although rarely diagnostic, it is often supportive. In conjunction with high-resolution CT scan, most patients with ILD can be diagnosed using relatively noninvasive methods...
  62. ncbi request reprint HLA and environmental interactions in sarcoidosis
    M D Rossman
    Division of Pulmonary, Allergy and Critical Care, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104 6160, USA
    Sarcoidosis Vasc Diffuse Lung Dis 25:125-32. 2008
    ..Future studies in defined phenotypes of sarcoidosis may be necessary to define environmental and genetic associations with sarcoidosis...
  63. pmc Rheumatologic manifestations of sarcoidosis
    Nadera J Sweiss
    Section of Rheumatology, Department of Medicine, University of Chicago Medical Center, Chicago, IL 60637, USA
    Semin Respir Crit Care Med 31:463-73. 2010
    ..We present two cases of sarcoidosis with rheumatologic manifestations. Our intent is to encourage a multidisciplinary, translational approach to meet the challenges and difficulties in understanding and treating sarcoidosis...
  64. doi request reprint Treatment of right ventricular dysfunction in pulmonary arterial hypertension: theoretical considerations
    Peter J Engel
    Pulmonary Hypertension Clinic, The Christ Hospital, Cincinnati, OH, USA
    Med Hypotheses 73:448-52. 2009
    ..This is a hypothesis which could be tested in an animal model of this condition...
  65. ncbi request reprint Pulmonary hypertension in neurofibromatosis
    Peter J Engel
    The Ohio Heart and Vascular Center, Cincinnati, Ohio, USA
    Am J Cardiol 99:1177-8. 2007
    ..The published research is reviewed. In conclusion, it is suggested that the association between these conditions be recognized in the classification of pulmonary hypertension...
  66. ncbi request reprint Nosocomial pneumonia: the gorilla in the ICU
    Robert P Baughman
    J Intensive Care Med 18:227-8. 2003
  67. ncbi request reprint Two year prognosis of sarcoidosis: the ACCESS experience
    Marc A Judson
    Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 29425, USA
    Sarcoidosis Vasc Diffuse Lung Dis 20:204-11. 2003
    ..Several factors associated with improved or worse outcome over two years were identified...
  68. ncbi request reprint The variability of sarcoidosis: can we predict it?
    Robert P Baughman
    Chest 123:1329-32. 2003
  69. ncbi request reprint The diagnostic pathway to sarcoidosis
    Marc A Judson
    Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston 29425, USA
    Chest 123:406-12. 2003
    ..To examine the time from the first physician visit to the diagnosis of sarcoidosis...
  70. ncbi request reprint Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts
    Nadera J Sweiss
    Section of Rheumatology and Immunology, University of Chicago, Chicago, IL 60637, USA
    Clin Dermatol 25:341-6. 2007
    ..The long-term safety and efficacy of such therapies are yet to be determined in well-designed clinical trials with long-term follow-up...
  71. ncbi request reprint A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis
    Milton D Rossman
    Hospital of the University of Pennsylvania, Philadelphia, PA, USA
    Sarcoidosis Vasc Diffuse Lung Dis 23:201-8. 2006
    ..To evaluate the safety and tolerability of infliximab in the treatment of active pulmonary sarcoidosis, and to provide an initial assessment of the efficacy of infliximab in the treatment of active pulmonary sarcoidosis...
  72. ncbi request reprint Systemic evaluation of a potential cutaneous sarcoidosis patient
    Ulrich Costabel
    Department of Pneumology Allergy, Ruhrlandklinik Essen, D 45239 Essen, Germany
    Clin Dermatol 25:303-11. 2007
    ..The evaluation leads to a wide number of organs being assessed by either history, physical examination or routine laboratory investigations. The major organs routinely assessed are the lungs, the eyes, the liver and the heart...
  73. ncbi request reprint The spectrum of biopsy sites for the diagnosis of sarcoidosis
    Alvin S Teirstein
    Mount Sinai Medical Center, New York, NY 10029, USA
    Sarcoidosis Vasc Diffuse Lung Dis 22:139-46. 2005
    ..Clinicians must decide which site offers the best chance of achieving a diagnostic biopsy with the least patient risk and discomfort...
  74. ncbi request reprint Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: slaying the dragon?
    Nadera J Sweiss
    J Rheumatol 34:2129-31. 2007
  75. ncbi request reprint Bronchoalveolar cellular analysis in scleroderma lung disease: does Sutton's law hold?
    Robert P Baughman
    Am J Respir Crit Care Med 177:2-3. 2008
  76. ncbi request reprint Pulmonary and psychosocial findings at enrollment in the ACCESS study
    Henry Yeager
    Pulmonary, Critical Care, and Sleep Medicine, Georgetown University Medical Center, Washington, DC 20057, USA
    Sarcoidosis Vasc Diffuse Lung Dis 22:147-53. 2005
    ..To assess lung involvement and the association of demographic and psychosocial factors with respiratory health in 736 persons with sarcoidosis at enrollment in A Case Control Etiologic Study of Sarcoidosis (ACCESS)...
  77. ncbi request reprint A case control etiologic study of sarcoidosis: environmental and occupational risk factors
    Lee S Newman
    National Jewish Medical and Research Center and Univresity of Colorado Health Scienes Center, Denver, CO 80206, USA
    Am J Respir Crit Care Med 170:1324-30. 2004
    ..65, CI 0.51-0.82). The study did not identify a single, predominant cause of sarcoidosis. We identified several exposures associated with sarcoidosis risk, including insecticides, agricultural employment, and microbial bioaerosols...
  78. ncbi request reprint Comparison of sarcoidosis phenotypes among affected African-American siblings
    Marc A Judson
    Division of Pulmonary and Critical Care Medicine CSB 812, Medical University of South Carolina, Charleston, SC 29425, USA
    Chest 130:855-62. 2006
    ..To test the hypothesis that sibling pairs, who share genes and environmental exposures, might have similar phenotypic expressions of sarcoidosis beyond what would be expected by chance alone...
  79. ncbi request reprint Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant
    Roger G Spragg
    Veteran s Administration Medical Center, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
    Am J Respir Crit Care Med 167:1562-6. 2003
    ..The presence of exogenous surfactant was not detected in lavage fluid obtained at 120 hours. Future studies might rationally employ larger surfactant doses and a more prolonged dosing schedule...
  80. ncbi request reprint Reverse phenotyping in sarcoidosis
    Michael C Iannuzzi
    Am J Respir Crit Care Med 175:4-5. 2007
  81. ncbi request reprint Health care-associated pneumonia (HCAP): a critical appraisal to improve identification, management, and outcomes--proceedings of the HCAP Summit
    Marin H Kollef
    Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Clin Infect Dis 46:S296-334; quiz 335-8. 2008
    ..The results were then compared with results of the same survey as completed by 744 Infectious Diseases Society of America members. The similarities and differences between those survey results are the basis of this publication...
  82. ncbi request reprint A sarcoidosis genetic linkage consortium: the sarcoidosis genetic analysis (SAGA) study
    Benjamin A Rybicki
    Department of Biostatistics and Research Epidemiology, Henry Ford Health System, Detroit, MI 48202, USA
    Sarcoidosis Vasc Diffuse Lung Dis 22:115-22. 2005
    ..In the United States of America, African Americans have a higher sarcoidosis incidence and suffer greater morbidity than Caucasians...
  83. ncbi request reprint Job and industry classifications associated with sarcoidosis in A Case-Control Etiologic Study of Sarcoidosis (ACCESS)
    Juliana Barnard
    Division of Environmental and Occupational Health Sciences, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA
    J Occup Environ Med 47:226-34. 2005
    ..To determine whether specific occupations and industries may be associated with sarcoidosis...